LifeMD to co-market XYOSTED self-pay program with Antares Pharma, launching July 2026 in 37 states
LifeMD entered into agreements with Antares Pharma, a subsidiary of Halozyme, to co-market a direct-to-patient self-pay program for XYOSTED, a testosterone injection. LifeMD will be the exclusive telehealth co-marketing partner, and its pharmacy will be the preferred dispensing pharmacy. The filing does not disclose financial terms or dollar amounts for the deal, so its near-term effect on LifeMD's results cannot be measured from this filing.
Key points
- The program launches in July 2026 and will initially be available in 37 states.
- The company's all-inclusive program price is approximately $249 per month, covering medication and care, per the attached press release.
- The agreements have an initial three-year term with automatic one-year renewals unless either party gives 90 days' written notice.
- Either party may terminate the Statement of Work if budgeted marketing investments are missed for two consecutive quarters.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.